Search

It is known that pentamidine can cause severe pancreatic toxicity in patients with the acquired immunodeficiency syndrome.1The most frequent and severe adverse event is hypoglycemia that occurs in 6% to 35% of patients assuming pentamidine with a higher incidence in those who are seropositive for the human immunodeficiency virus.2Occasionally, hyperglycemia and acute pancreatitis have also been reported.3Diabetes mellitus is a much less commonly recognized complication. Only a few cases have been reported in the literature and the real incidence of diabetes mellitus developing after intravenous pentamidine therapy is unknown.2,4,5 We describe a case of transient diabetes mellitus presenting after pentamidine therapy in a patient with the acquired immunodeficiency syndrome. Report of a Case. A 29-year-old man who was an intravenous drug user became infected with the human immunodeficiency virus in 1986. He was admitted to our hospital with a diagnosis ofPneumocystis carinii